Drug-eluting bead transcatheter arterial chemoembolization (DEB-TACE) is commonly used to treat unresectable hepatitis B-related primary liver cancer, but its therapeutic effect is influenced by various factors.
This study analyzes the clinical factors related to the overall survival (OS) and progression-free survival (PFS) of patients with hepatitis B-related hepatocellular carcinoma (HCC) treated with DEB-TACE to provide reference data for individualized treatment.
